Literature DB >> 29955496

Ayahuasca: An ancient sacrament for treatment of contemporary psychiatric illness?

Benjamin J Malcolm1, Kelly C Lee2.   

Abstract

Ayahuasca is a traditional psychoactive sacrament that's been used in Amazonian shamanic rituals for hundreds of years. Ayahuasca is notorious for its psychedelic properties produced from the combination of monoamine oxidase inhibitors (MAOIs) found in the Banisteriopsis caapi vine and N-N-dimethyltryptamine from Psychotria viridis or Diplopterys cabrerana. Recently, ritual use of ayahuasca has increased and garnered attention for its potential in treating mental illnesses, such as substance use and depressive disorders. Due to its MAOI properties, there are serious drug interactions that may be of concern among patients who participate in ayahuasca use. The objectives of this paper are to describe ayahuasca's pharmacology, potential drug interactions, and clinical data for its treatment potential in psychiatric illness.

Entities:  

Keywords:  ayahuasca; dimethyltryptamine; harmine; monoamine oxidase; sacrament

Year:  2018        PMID: 29955496      PMCID: PMC6007657          DOI: 10.9740/mhc.2017.01.039

Source DB:  PubMed          Journal:  Ment Health Clin        ISSN: 2168-9709


  70 in total

1.  Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers.

Authors:  J Riba; A Rodríguez-Fornells; G Urbano; A Morte; R Antonijoan; M Montero; J C Callaway; M J Barbanoj
Journal:  Psychopharmacology (Berl)       Date:  2001-02       Impact factor: 4.530

2.  Ayahuasca-assisted therapy for addiction: results from a preliminary observational study in Canada.

Authors:  Gerald Thomas; Philippe Lucas; N Rielle Capler; Kenneth W Tupper; Gina Martin
Journal:  Curr Drug Abuse Rev       Date:  2013-03

3.  Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor.

Authors:  J R Bunzow; M S Sonders; S Arttamangkul; L M Harrison; G Zhang; D I Quigley; T Darland; K L Suchland; S Pasumamula; J L Kennedy; S B Olson; R E Magenis; S G Amara; D K Grandy
Journal:  Mol Pharmacol       Date:  2001-12       Impact factor: 4.436

4.  Pharmacokinetics of Hoasca alkaloids in healthy humans.

Authors:  J C Callaway; D J McKenna; C S Grob; G S Brito; L P Raymon; R E Poland; E N Andrade; E O Andrade; D C Mash
Journal:  J Ethnopharmacol       Date:  1999-06       Impact factor: 4.360

5.  N,N-Dimethyltryptamine-Induced Psychosis.

Authors:  Neil E Paterson; W Connor Darby; Preetpal S Sandhu
Journal:  Clin Neuropharmacol       Date:  2015 Jul-Aug       Impact factor: 1.592

6.  Evidence of health and safety in American members of a religion who use a hallucinogenic sacrament.

Authors:  John H Halpern; Andrea R Sherwood; Torsten Passie; Kimberly C Blackwell; A James Ruttenber
Journal:  Med Sci Monit       Date:  2008-08

7.  Hypotheses regarding the mechanisms of ayahuasca in the treatment of addictions.

Authors:  Mitchell B Liester; James I Prickett
Journal:  J Psychoactive Drugs       Date:  2012 Jul-Aug

8.  Ritualistic Use of Ayahuasca versus Street Use of Similar Substances Seized by the Police: A Key Factor Involved in the Potential for Intoxications and Overdose?

Authors:  Rafael Lanaro; Débora Bressanim de Aquino Calemi; Loraine Rezende Togni; José Luiz Costa; Maurício Yonamine; Silvia de Oliveira Santos Cazenave; Alessandra Linardi
Journal:  J Psychoactive Drugs       Date:  2015 Apr-Jun

Review 9.  Translating the evidence on atypical depression into clinical practice.

Authors:  Mark Hyman Rapaport
Journal:  J Clin Psychiatry       Date:  2007       Impact factor: 4.384

10.  Broadband cortical desynchronization underlies the human psychedelic state.

Authors:  Suresh D Muthukumaraswamy; Robin L Carhart-Harris; Rosalyn J Moran; Matthew J Brookes; Tim M Williams; David Errtizoe; Ben Sessa; Andreas Papadopoulos; Mark Bolstridge; Krish D Singh; Amanda Feilding; Karl J Friston; David J Nutt
Journal:  J Neurosci       Date:  2013-09-18       Impact factor: 6.167

View more
  6 in total

1.  [Ayahuasca-induced psychosis in a patient with bipolar disorder].

Authors:  Nicolas Zellner; Tobias Zellner; Jan Warninghoff
Journal:  Nervenarzt       Date:  2019-11       Impact factor: 1.214

Review 2.  Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression.

Authors:  Susan Ling; Felicia Ceban; Leanna M W Lui; Yena Lee; Kayla M Teopiz; Nelson B Rodrigues; Orly Lipsitz; Hartej Gill; Mehala Subramaniapillai; Rodrigo B Mansur; Kangguang Lin; Roger Ho; Joshua D Rosenblat; David Castle; Roger S McIntyre
Journal:  CNS Drugs       Date:  2021-11-17       Impact factor: 5.749

Review 3.  Psychedelic Therapies at the Crossroads of Trauma and Substance Use: Historical Perspectives and Future Directions, Taking a Lead From New Mexico.

Authors:  Snehal R Bhatt; Maya Armstrong; Tassy Parker; Marcello Maviglia; Rebecca Kass; Lawrence Leeman; Paul Romo; Douglas Ziedonis
Journal:  Front Pharmacol       Date:  2022-06-27       Impact factor: 5.988

4.  Evaluation of the Cytotoxicity of Ayahuasca Beverages.

Authors:  Ana Y Simão; Joana Gonçalves; Ana Gradillas; Antonia García; José Restolho; Nicolás Fernández; Jesus M Rodilla; Mário Barroso; Ana Paula Duarte; Ana C Cristóvão; Eugenia Gallardo
Journal:  Molecules       Date:  2020-11-28       Impact factor: 4.411

Review 5.  Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.

Authors:  Henry Lowe; Ngeh Toyang; Blair Steele; Justin Grant; Amza Ali; Lorenzo Gordon; Wilfred Ngwa
Journal:  Molecules       Date:  2022-04-14       Impact factor: 4.927

Review 6.  Serotonin toxicity of serotonergic psychedelics.

Authors:  Benjamin Malcolm; Kelan Thomas
Journal:  Psychopharmacology (Berl)       Date:  2021-07-12       Impact factor: 4.530

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.